- Details
- Alicia Morgans invites Tia Higano to discuss data analysis amongst patients with mCRPC who were enrolled in the Flatiron Health prostate cancer registry from 2013-2017. Findings include the discovery that 77% of patients receive some form of life-prolonging therapy and that only 60% of the patients ever received either denosumab or zoledronic acid. Alicia and Tia conclude by stating the importance...
|
- Details
- Susan Halabi discusses new findings in the evaluation of racial disparities in progression-free survival across nine trials. Biographies: Susan Halabi Ph.D Professor of Biostatistics and Bioinformatics. Duke Cancer Institute Alicia Morgans, MD, MPH , Associate Professor of Medicine in the Division of Hematology/Oncology at the Northwestern University Feinberg School of Medicine in Chicago, Illinoi...
|
- Details
- Martin Felices discusses a unique approach to using natural killer (NK) cells to target a variety of cancers. NK cells seek out abnormal cells while also producing inflammatory cytokines that induce the adaptive immune response. There is a known role of NK cells in hematologic malignancies whereas in tumor micro environments the NK cells display characteristics of exhaustion and lack of maturation...
|
- Details
- Neal Shore and Oliver Sartor cover the topic of racial disparities in prostate cancer and the use of immunotherapy particularly sipuleucel-T in the African American community. Oliver does a deep dive into the double-blind, placebo-controlled, multicenter trial, Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) study, involving 512 men with metastatic castration-resistant prostate cancer...
|
- Details
- Wassim Abida joins Charles Ryan in a discussion on a JAMA Oncology published paper on the Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. Wassim details the prevalence of MSI-H/dMMR prostate cancer and the clinical benefit of anti–PD-1/programmed cell death 1 ligand 1 (PD-L1) therapy in this molecularly defined population. The...
|
- Details
- Richard Lee, a 2017 PCF Challenge Award recipient, discusses his research on the metabolics of prostate cancer. The upcoming Phase 1 research in men with CRPC is centered around inhibiting the glutaminase pathway in combination with a PARP inhibitor. The rationale for targeting the glutaminase pathway stems from the fact that cancer cells deplete glucose as a carbon source, a necessary element for...
|
- Details
- Suresh C. Srivastava presents the unique opportunities and future for nuclear medicine, including theragnostic radiopharmaceuticals for molecular imaging plus therapy and getting closer to personalized medicine, selection criteria, production, and the nuclear, physical, and chemical properties of certain dual-purpose radionuclides, including those that are currently being used, or studied and eval...
|
- Details
- (Length of Discussion: 12 min) Charles Ryan and Andrew Armstrong discuss the PROPHECY study, a PCF challenge award, co-funded by Movember. Seeing the future with predictive biomarkers was the foundational vision for this study. For men with castration-resistant prostate cancer undergoing a range of therapies, two AR-V7 tests were prospectively compared to see how well they predicted both progressi...
|
- Details
- (Length of Discussion: 16 min) Charles Ryan and Ken Pienta discuss the process of metastasis in prostate cancer, referring to the seed and soil hypothesis and the influence of the tumor microenvironment and immune system. Biography: Kenneth J. Pienta, MD, The Donald S. Coffey Professor of Urology, Professor of Oncology, Professor of Pharmacology and Molecular Sciences, The Johns Hopkins Hospital R...
|
- Details
- Noel Clarke shares a recent update in his work focused on the PARP inhibitor, olaparib for patients with castration-resistant prostate cancer (CRPC) in combination with abiraterone. Biographies: Noel W Clarke, Professor of Urologic Oncology, Director of the Genitourinary Research Group, Manchester University, Consultant Urologist at Salford Royal Hospital and The Christie, Manchester Charles J. Ry...
|
